Supernus Pharma (SUPN) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Supernus Announces Second Quarter 2016 Financial Results
August 2, 2016 4:30 PM EDTSecond quarter 2016 product prescriptions totaled 123,758, a 38.9% increase over the second quarter of 2015.Net product sales for second quarter 2016 were $50.3 million, a 46.9% increase over the second quarter of 2015.Operating income for second quarter 2016 was $10.4 million compared to $3.1 million in the second quarter of 2015.   Diluted earnings per share in the second quarter were $0.18 compared to $0.03 in the same period last year.   Enrollment completed in SPN-812 Phase IIb trial. Enrollment for SPN-810 Phase III trials expected to continue into 2017.
ROCKVILLE, Md., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:... More
